Reported 11 months ago
A new study published in the New England Journal of Medicine suggests that tirzepatide, found in the obesity drug Zepbound and the diabetes treatment Mounjaro, may help reduce the severity of sleep apnea in patients with obesity. The drug also led to weight loss, improved blood pressure, and other health measures. Eli Lilly and Co. is seeking FDA approval to expand the drug's use to treat moderate to severe sleep apnea. However, more research is needed to determine if tirzepatide can be used as a sole treatment for obstructive sleep apnea, which affects an estimated 20 million Americans and can lead to various health issues.
Source: YAHOO